
- /
- Supported exchanges
- / US
- / GANX.NASDAQ
Gain Therapeutics Inc (GANX NASDAQ) stock market data APIs
Gain Therapeutics Inc Financial Data Overview
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Gain Therapeutics Inc data using free add-ons & libraries
Get Gain Therapeutics Inc Fundamental Data
Gain Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -20 314 820
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gain Therapeutics Inc News

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and developme...


Gain Therapeutics stock falls after announcing public offering
Investing.com -- Gain Therapeutics Inc (NASDAQ:GANX) stock fell 11% after the clinical-stage biotechnology company announced plans for an underwritten public offering of common stock and warrants to...

Gain Therapeutics announces proposed public offering
* Gain Therapeutics (NASDAQ:GANX [https://seekingalpha.com/symbol/GANX]) announced on Tuesday that it is proposing to offer and sell shares of its common stock and warrants to purchase common stock ...

Gain Therapeutics Announces Proposed Public Offering
BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and developme...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.